Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease

Movement Disorders

Volumn 31, Issue 10, 2016, Pages 1518-1526

  Malek, Naveed ^a   Lawton, Michael A ^b   Swallow, Diane M A ^a   Grosset, Katherine A ^a   Marrinan, Sarah L ^c   Bajaj, Nin ^d   Barker, Roger A ^e   Burn, David J ^c   Hardy, John ^f   Morris, Huw R ^g   Williams, Nigel M ^h   Wood, Nicholas ^g   Ben Shlomo, Yoav ^b   Grosset, Donald G ^a  

^a QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

cerebrovascular; diabetes; gender; Parkinson's disease; phenotype

Indexed keywords

CHOLESTEROL; LEVODOPA;

AGED; ANGINA PECTORIS; ARTICLE; BRAIN INFARCTION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; COHORT ANALYSIS; COMORBIDITY; DEMENTIA; DIABETES MELLITUS; DISEASE DURATION; FEMALE; FUNCTIONAL DISEASE; GAIT DISORDER; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LEUKOARAIOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MONTREAL COGNITIVE ASSESSMENT; MOTOR DYSFUNCTION; NEUROIMAGING; OBESITY; OBSERVATIONAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; TRANSIENT ISCHEMIC ATTACK; UNIFIED PARKINSON DISEASE RATING SCALE; VASCULAR DISEASE;

EID: 84991226743     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26698     Document Type: Article

References (44)

1. Hu MT, Szewczyk-Krolikowski K, Tomlinson P, et al. Predictors of cognitive impairment in an early stage Parkinson's disease cohort. Mov Disord 2014;29:351–359.
2. Pfeiffer HC, Lokkegaard A, Zoetmulder M, Friberg L, Werdelin L. Cognitive impairment in early-stage non-demented Parkinson's disease patients. Acta Neurol Scand 2014;129:307–318.
3. Wardlaw JM, Valdes Hernandez MC, Munoz-Maniega S. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. Am Heart J 2015; 4:001140.
4. Hajjar I, Quach L, Yang F, et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the Cardiovascular Health Study. Circulation 2011;123:858–865.
5. Verdelho A, Madureira S, Ferro JM, et al. Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry 2007;78:1325–1330.
6. Dearborn JL, Knopman D, Sharrett AR, et al. The metabolic syndrome and cognitive decline in the Atherosclerosis Risk in Communities study (ARIC). Dement Geriatr Cogn Disord 2014;38:337–46.
7. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord 2013;28:668–670.
8. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006;21:1123–1130.
9. Rosano C, Brach J, Studenski S, Longstreth WT Jr, Newman AB. Gait variability is associated with subclinical brain vascular abnormalities in high-functioning older adults. Neuroepidemiology 2007;29:193–200.
10. Hashimoto M, Takashima Y, Uchino A, Yuzuriha T, Yao H. Dual task walking reveals cognitive dysfunction in community-dwelling elderly subjects: the Sefuri brain MRI study. J Stroke Cerebrovasc Dis 2014;23:1770–1775.
11. Kotagal V, Albin RL, Muller ML, Koeppe RA, Frey KA, Bohnen NI. Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord 2013;19:522–526.
12. Bohnen NI, Muller ML, Zarzhevsky N, et al. Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease. Brain 2011;134:2358–2365.
13. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement 2015;11:718–726.
14. Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 2011;82:1112–1118.
15. Bloem BR, Grimbergen YA, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson's disease. J Neurol 2001;248:950–8.
16. Santiago JA, Potashkin JA. System-based approaches to decode the molecular links in Parkinson's disease and diabetes. Neurobiol Dis 2014;72(Pt A):84–91.
17. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497–1499.
18. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649–2653.
19. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689–1707; quiz 837.
20. The QRISK®2–2015 risk calculator. http://www.qrisk.org. Accessed April 4, 2016.
21. Rubin DB. Inference and missing data. Biometrika 1976;63:581–592.
22. Buchman AS, Leurgans SE, Nag S, Bennett DA, Schneider JA. Cerebrovascular disease pathology and parkinsonian signs in old age. Stroke 2011;42:3183–3189.
23. Chaudhari TS, Verma R, Garg RK, Singh MK, Malhotra HS, Sharma PK. Clinico-radiological predictors of vascular cognitive impairment (VCI) in patients with stroke: a prospective observational study. J Neurol Sci 2014;340:150–158.
24. Verghese J, Ayers E, Barzilai N, et al. Motoric cognitive risk syndrome: multicenter incidence study. Neurology 2014;83:2278–2284.
25. Mahlknecht P, Kiechl S, Willeit J, Poewe W, Seppi K. Motoric cognitive risk syndrome: multicenter incidence study. Neurology 2015;85:388–389.
26. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480–486.
27. Guan J, Pavlovic D, Dalkie N, et al. Vascular degeneration in Parkinson's disease. Brain Pathol 2013;23:154–164.
28. Spauwen PJ, van Boxtel MP, Verhey FR, et al. Both low and high 24-hour diastolic blood pressure are associated with worse cognitive performance in type 2 diabetes: the Maastricht study. Diabetes Care 2015;38:1473–1480.
29. Park K, Yasuda N, Toyonaga S, et al. Significant association between leukoaraiosis and metabolic syndrome in healthy subjects. Neurology 2007;69:974–978.
30. Mak E, Dwyer MG, Ramasamy DP, et al. White matter hyperintensities and mild cognitive impairment in Parkinson's disease. J Neuroimaging 2015;25:754–760.
31. Beyer MK, Aarsland D, Greve OJ, Larsen JP. Visual rating of white matter hyperintensities in Parkinson's disease. Mov Disord 2006;21:223–229.
32. Vesely B, Rektor I. The contribution of white matter lesions (WML) to Parkinson's disease cognitive impairment symptoms: a critical review of the literature. Parkinsonism Relat Disord 2016;22(suppl 1):S166–S170.
33. Slawek J, Wieczorek D, Derejko M, et al. The influence of vascular risk factors and white matter hyperintensities on the degree of cognitive impairment in Parkinson's disease. Neurol Neurochir Pol 2008;42:505–512.
34. Meyer JS, Huang J, Chowdhury MH. MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias. J Neurol Sci 2007;257:97–104.
35. Slawek J, Roszmann A, Robowski P, et al. The impact of MRI white matter hyperintensities on dementia in Parkinson's disease in relation to the homocysteine level and other vascular risk factors. Neurodegener Dis 2013;12:1–12.
36. Lee SJ, Kim JS, Yoo JY, et al. Influence of white matter hyperintensities on the cognition of patients with Parkinson disease. Alzheimer Dis Assoc Disord 2010;24:227–233.
37. Kandiah N, Mak E, Ng A, et al. Cerebral white matter hyperintensity in Parkinson's disease: a major risk factor for mild cognitive impairment. Parkinsonism Rel Disord 2013;19:680–3.
38. Gonzalez-Redondo R, Toledo J, Clavero P, et al. The impact of silent vascular brain burden in cognitive impairment in Parkinson's disease. Eur J Neurol 2012;19:1100–1107.
39. Bohnen NI, Kotagal V, Muller ML, et al. Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Rel Disord 2014;20:1394–1398.
40. Chen YF, Tseng YL, Lan MY, et al. The relationship of leukoaraiosis and the clinical severity of vascular Parkinsonism. J Neurol Sci 2014;346:255–259.
41. Vesely B, Antonini A, Rektor I. The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature. J Neural Transm (Vienna). 2015;123:241–250.
42. Cereda E, Barichella M, Cassani E, Caccialanza R, Pezzoli G. Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology 2012;78:1507–1511.
43. Rektor I, Goldemund D, Sheardova K, Rektorova I, Michalkova Z, Dufek M. Vascular pathology in patients with idiopathic Parkinson's disease. Parkinsonism Rel Disord 2009;15:24–29.
44. Olanow CW, Wunderle KB, Kieburtz K. Milestones in movement disorders clinical trials: advances and landmark studies. Mov Disord 2011;26:1003–14.